ganciclovir + meropenem + vancomycin

This combination therapy consists of the antiviral agent **ganciclovir**, the carbapenem antibiotic **meropenem**, and the glycopeptide antibiotic **vancomycin**. It is typically utilized in the management of critically ill patients, particularly those in pediatric or adult intensive care units presenting with severe sepsis, multiple organ dysfunction, or necrotizing pneumonia where broad-spectrum antimicrobial coverage is required. Ganciclovir is a nucleoside analog that inhibits viral DNA polymerase, providing activity against cytomegalovirus (CMV) reactivation, a common complication in immunocompromised or critically ill patients. Meropenem is a broad-spectrum carbapenem that targets Gram-negative and Gram-positive bacteria by inhibiting cell wall synthesis through binding to penicillin-binding proteins (PBPs). Vancomycin provides targeted coverage against Gram-positive organisms, including methicillin-resistant *Staphylococcus aureus* (MRSA), by binding to the D-alanyl-D-alanine portion of cell wall precursors, thereby inhibiting peptidoglycan polymerization.